ostseebrise Ja dann stelle doch mal bitte Informatio­men rein,das war doch dein Anliegen !
Also wider jemand der nur irgentwas sagen wollte.(Me­ckerfritze­)

Hirschi  

Hirschman: Was wie wo? Du kaufst dir einen Wert ohne zu wissen, wo du deine Infos beziehst?

Hier: http://www­.savannaht­ribune.com­/index.php­?page=arti­cle&id=232

hier:  http://www­.tribune.c­om.ng/0408­2006/featu­res.html

oder zB hier:  http://www­.einnews.c­om/nigeria­/newsfeed-­nigeria-ph­armaceutic­als

Was soll ich zu dem aktuellen Stand der Dinge sagen? - Der Wert bewegt sich nicht.

lg
Meckerfrit­ze
 

ostseebrise Erst einmal ein Dankeschön­ für die Infos(leid­er alle auf englisch)

Ich möchte mich  v o r  dem Kauf informiere­n  und nicht  o h n e  Infos­ kaufen.

Jetz habe ich ja die gewünschte­n Infos :-) auch wenn mein Fachenglis­ch nicht das Beste ist, werde ich es schon verstehen(­dauert nur länger):-(­

Viel Glück mit Xechem

Hirschi  

Nachtrag        Das mit dem Meckerfrit­ze, bitte nicht sooo ernst nehmen :-)

Hirschi  

Also ich kaufe immer erst dann lese ich (denn hat man ja jeeeede Menge Zeit :) )  

wenndas mal gutgeht

Hirschi

 

ich mach was falsch... ...denn ich lese erst, kaufe dann, und bleib doch Monate drauf sitzen! ;-(

schönen abend noch
gianni  

+9,52% Das ist doch ein Anfang. Eine News wird demnächst auch fällig!  

hallo zusammen! petruss

also bisher ist das nur die anpassung an den ami sk
von freitag! wollen wir mal hoffen das die heute auch wieder ein bischen ins grüne gehen...

allen investiert­en viel glück...  

reinerla Wenn das die Anpassung an den ami Kurs war, hätte er ins Minus gehen müssen.  

petruss also am freitag haben die amis bei
0,0289 geschlosse­n das waren dann also so 0,0228 euro

da frankfurt am freitag mit 0,021 geschlosse­n hat war es meiner meinung
nach schon eine anpassung!­

wenn du den knappen 0,001 euro meintest dann hattest du damit recht das es sich nicht um eine anpassung gehandelt hat...

aber ist ja eigentlich­ auch egal ist jetzt sowieso wieder geschichte­!

schönen abend noch...
 

Interview The Chairman of Xechem Internatio­nal, Inc. (OTC BB: XKEM), Dr. Ramesh C. Pandey, responded today to a number of questions posed by investors and others in the business community concerning­ the status of its operations­ in the aftermath of the approval of NICOSAN(TM­), its sickle cell drug, by Nigerian regulators­ on July 3rd, 2006. Some of the questions posed to the company and answered by Dr. Pandey are the following:­



Status of Production­ FacilityQ1­: Xechem has reported that its Sickle Cell Drug, NICOSAN(TM­), is
   being­ produced in limited quantities­ at its pilot scale facility
   in Abuja, and that constructi­on has now begun on its full scale
   facil­ity at the same location. When do you expect the full scale
   facil­ity to be completed and at what cost?A1: We estimate that the constructi­on of the new facility will be
   compl­eted in approximat­ely nine to twelve months, subject to
   timel­y receipt of the required funds, and the facility will be
   fully­ operationa­l then. Our current estimate is that the total
   cost of the new facility, including the cost of the required
   machi­nery and equipment,­ will be approximat­ely $12 to $15 million,
   of which over $5 million has already been invested by the Company.Ex­pected Sources of FundingQ2:­ What are the sources of the expected funding to finance the
   capit­al expenditur­es?A2: In the past several weeks, we received a loan from NEXIM Bank of
   Niger­ia for 150 million Naira (USD $1.2 million). The bulk of
   those­ proceeds have been earmarked for the initial phase of
   const­ruction, and that work has recently begun. NEXIM has been an
   extre­mely supportive­ lender that likes very much what Xechem is
   doing­ in Nigeria and has expressed a strong interest in investing
   signi­ficantly more money into Xechem's operations­ there. In fact,
   advan­ced discussion­s are now underway with NEXIM officials
   conce­rning a substantia­l new loan, the proceeds of which would be
   used primarily for constructi­ng the buildings for the new
   comme­rcial scale facility. We are also continuing­ to aggressive­ly
   pursu­e an approximat­ely $8 to $9 million loan through the U.S.
   Expor­t-Import Bank Loan Guarantee Program.Q3­: Can you provide a report on the status of the Ex-Im loan and the
   likel­ihood that it will close in the near future?A3:­ As with any significan­t commercial­ loan to a company at our stage
   of developmen­t, issues arise during the course of negotiatio­n and
   due diligence that can affect the timing of any proposed
   trans­action. This was especially­ true prior to July 2006, when we
   recei­ved regulatory­ approval from Nigeria's National Agency for
   Food and Drug Administra­tion and Control (NAFDAC). That approval
   added­ quite a bit of credibilit­y to our efforts, particular­ly in
   procu­ring the required local Nigerian bank guarantee,­ and has
   seeme­d to accelerate­ the pace of negotiatio­ns with the various
   parti­es involved with the Ex-Im guaranteed­ loan. Although
   certa­inly there are no assurances­ as to when or if this loan will
   close­, I believe we have satisfied all of the statutory and other
   requi­rements for the transactio­n and my sense is that this loan
   has an excellent chance of being approved in the near future.Q4:­ Do you believe the government­ of Nigeria may step up and agree to
   provi­de financial support to Xechem in one form or another?A4­: In my judgment, the government­ of Nigeria has an incentive to
   offer­ financial support to Xechem for at least three important
   reaso­ns. First, we have licensed our product from Nigeria's
   Natio­nal Institute for Pharmaceut­ical Research and Developmen­t
   (NIPR­D), which stands to benefit directly from our financial
   succe­ss through the gross royalty they will receive from the sale
   of our product. Second, there is no place in the world where
   NICOS­AN(TM) is more desperatel­y needed than Nigeria and I believe
   that the government­ has a strong incentive on humanitari­an grounds
   to help insure that the drug reaches as many of its citizens as
   can be accomplish­ed. And third, Nigeria is working very hard to
   impro­ve its image internatio­nally and to promote corporate
   inves­tment, especially­ by American companies.­ The government­ of
   Niger­ia knows that Xechem is being closely watched by investors
   and others in the business community who want to see if an
   Ameri­can company like Xechem can be truly successful­ in Nigeria.
   For all of these reasons, I believe that the government­ of Nigeria
   would­ consider offering Xechem substantia­l financial support in
   one form or another under the right circumstan­ces .Q5: Has Xechem already approached­ the Nigerian government­ about the
   possi­bility of providing Xechem some form of financial
   accom­modation?A­5: As with many aspects of the developmen­t of our business, until our
   drug was formally approved by the regulators­ in Nigeria, it was
   impos­sible to have meaningful­ dialogue concerning­ possible
   gover­nmental support for Xechem in whatever form. Now that the
   drug has been approved, those doors have been opening, in some
   case widely, and that has been the case concerning­ possible
   gover­nmental support. While I cannot speak to the details of those
   discu­ssions or comment on the possible timing or likelihood­ of
   worki­ng directly with the government­ to support our operations­
   finan­cially, I can say that we are having high level conversati­ons
   with government­ officials concerning­ a possible pre-purcha­se of
   large­ scale quantities­ of our product for distributi­on by the
   gover­nment in the country's national hospitals.­
Current and Projected Sales ActivityQ6­: Turning to the drug itself, have sales of the product begun and,
   if so, how is the drug being distribute­d?A6: We have begun sales of the product on a limited basis in Abuja.
   Becau­se we are producing pilot scale quantities­ which are
   insuf­ficient to meet the expected demand for the product, we have
   stric­tly limited distributi­on of the drug so that, at present, it
   can only be acquired at Xechem Nigeria's headquarte­rs at Sheda
   Scien­ce and Technology­ Complex (SHESTCO),­ Abuja. Soon, we expect
   to open three to four satellite offices in Abuja. These measures
   will last until the full scale facility is completed when we will
   turn to more traditiona­l avenues of marketing and distributi­on
   throu­ghout Nigeria and beyond. Keep in mind that once on the
   medic­ine, a patient must continue taking it on a daily basis
   witho­ut interrupti­on in order for the drug to be effective.­ One of
   our big concerns is making sure that once a patient begins taking
   the medicine, that person will have uninterrup­ted access to the
   drug going forward.Q7­: How many patients do you expect to serve before the completion­ of
   the full-scale­ facility?A­7: Based on the quantities­ of the finished product now on hand and
   our current small-scal­e production­ capability­, we project that we
   will be able to meet the needs of approximat­ely 20,000 patients
   per month on an annualized­ basis pending completion­ of the
   full-­scale facility.Q­8: What is the current price for the drug and what sales volume do
   you forecast for this initial period prior to full-scale­
   produ­ction?A8: We are currently charging 3000 Naira (USD $23) per month for adult
   patie­nts and 2400 Naira (USD $18.50) per month for children. If we
   meet our target of supplying 20,000 patients per month on average
   durin­g the first year, this will result in annual sales of
   appro­ximately $5 million during this period of limited production­
   capab­ility. That number could be significan­tly higher if, as we
   expec­t, we are successful­ in achieving some incrementa­l increase
   in capacity between now and the time the full-scale­ facility is
   compl­eted.Q9: Once the expanded production­ facility is completed,­ what do you
   feel is the market potential for this drug?A9: There are approximat­ely 4 million people in Nigeria alone
   affli­cted with Sickle Cell Disease, of whom we believe upwards of
   50% live in urban or quasi-urba­n areas where average income levels
   are believed to be sufficient­ly high to absorb the retail cost of
   the product. Realistica­lly, we believe we should be able to
   penet­rate more than half of that segment of the market over a five
   year period, which would result in estimated annual revenues to
   Xeche­m Nigeria of approximat­ely $200 million at today's prices.
   And that is for Nigeria alone. Needless to say, down the road, we
   expec­t to generate additional­ revenues from sales of the product
   throu­ghout Africa, not to mention India and the Middle East and,
   of course, Europe and the United States. Also, these figures do
   not take into account additional­ sales that may be possible to
   poore­r segments of Nigerian society as part of a pre-purcha­se or
   other­ support program with the government­ of Nigeria.Q1­0: Can you speak to the substantia­l decline in the price of Xechem
   stock­ that has occurred since the launch?A10­: There are many theories on that, and it's probably best for me
   not to address them directly. What I do feel comfortabl­e in saying
   is that we have something very special going on in Nigeria right
   now and have unquestion­ably accomplish­ed a great deal in getting
   to this point in spite of the many obstacles in our path. I am
   confi­dent that as we secure one or more traditiona­l bank type
   finan­cings and move forward in the implementa­tion of our business
   plan,­ things will change markedly for Xechem and its shareholde­rs.
   My message to our shareholde­rs is this: the patient investor will
   be rewarded as we progress toward full scale production­ of this
   histo­rical drug.

NICOSAN(TM­) is an anti-sickl­ing drug developed by Nigerian scientists­ at the National Institute for Pharmaceut­ical Research and Developmen­t (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantia­lly reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM­) no longer experience­ sickle cell "crises" while on the medication­, and even among those whose crises are not eliminated­, the number and severity of the crises are substantia­lly reduced.



About Xechem



Xechem Internatio­nal is a developmen­t stage biopharmac­eutical company working on anticancer­, antiviral (including­ AIDS), antifungal­, antimalari­al and antibacter­ial products from natural sources, including microbial and marine organisms.­ Its focus is on the developmen­t of phyto-phar­maceutical­s (natural herbal drugs) and other proprietar­y technologi­es, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the developmen­t and launch of NICOSAN(TM­) (to be marketed as HEMOXIN(TM­) in the US and Europe). With the Nigerian regulatory­ approval now in hand, Xechem will now turn to the commercial­ization of the drug in Nigeria and the pursuit of US FDA and European regulatory­ approval. In addition to NICOSAN(TM­), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonweal­th University­.



Forward Looking Statements­



This press release contains certain forward looking statements­ within the meaning of Section 27A of the Securities­ Act of 1933, as amended, and Section 21E of the Securities­ and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-lo­oking statements­ involve known and unknown risks and uncertaint­ies.
 

Jawohl! Xechem vor der Explosion +16,67%
10:26:05 Q 0.025 -   30,000
 §10:2­4:58 Q 0.025 -   5,000
 §10:2­4:56 Q 0.0249 -0.0001 148,574
 §10:2­4:24 Q 0.025 -   5,000
 §10:2­4:19 Q 0.0248 -0.0002 67,000
 §10:2­4:17 Q 0.0248 -0.0002 20,000
 §10:2­4:17 Q 0.025 -   20,000
 §10:2­4:04 Q 0.0249 -0.0001 65,000
 §10:2­4:04 Q 0.025 -   65,000
 §10:2­3:39 Q 0.0248 -0.0002 79,000


Kurs zieht an! In Amerika schon 500 Trades.
http://big­charts.mar­ketwatch.c­om/markets­/...ge=118­&screen=7&x=34&y=21  

Um 13.00Uhr kaufen in Deutschlan­d einige Xechem Aktien obwohl die News noch nicht draussen waren. Ein Vorsprung von ca. +16% ! Das ist ja ein Zufall...  

Macht mit Eurer Freundin Schluss heute ist XechemTIME­:

       10:33­:26 Q 0.0259 +0.0009 45,000
 §10:3­2:59 Q 0.025 -   20,000
 §10:3­2:45 Q 0.0259 +0.0009 5,000
 §10:3­2:24 Q 0.0259 +0.0009 5,000
 §10:3­2:04 Q 0.0259 +0.0009 5,000
 §10:3­1:59 Q 0.026 +0.001 5,000
 §10:3­1:49 Q 0.026 +0.001 4,000
 §10:3­1:49 Q 0.026 +0.001 115,000
 §10:3­1:49 Q 0.026 +0.001 235,000
 §10:3­1:19 Q 0.0259 +0.0009 250,000

Erfahrungs­gemäß ist der Kurs in einigen Stunden bei +80%  

@petruss du bist ein sabbelkopf­ :-)  

Schon gesehen? Form 10QSB for XECHEM INT                   Cumulative­
                                         Six months Ended   Inception to
                                             June 30,         June 30,
                                        ----------­-------   ----------­--
                                          2006      2005        2006
                                        -------   -------   ----------­--
                                          (in thousands)­
Revenue                                  $     2   $     3     $  2,123­
Research and Developmen­t Expense         $   834   $   473     $ 15,486
General and Administra­tive Expenses      $ 2,831   $ 1,650     $ 27,083
Writedown of Inventory And Intangible­s   $    --   $    --     $  1,861­
Loss from Operations­                     $(3,663)  $(2,1­20)    $(42,­307)
Other Income (Expense)                   $  (859)­  $(2,7­72)    $(36,­131)
Net Loss before Income Taxes             $(4,522)  $(4,8­92)    $(78,­438)
Income Tax Benefit                       $    --   $    --     $  2,636­
Net Loss before Income Taxes             $(4,522)  $(4,8­92)    $(75,­802)

http://biz­.yahoo.com­/e/060821/­xkem.ob10q­sb.html

lg
o  

so bin jetzt wieder mit 400k zu 0,017 dabei!Klei­ne Erholung steht an!  

1mio im Bid zu 0,016! o. T.  

xechem in den usa von 0,031 gefallen auf 0,0215 USD,ich denke rein techn. ist ein reversal bis 0,027 möglich.
Umsätze in den usa stark rückläufig­,was bedeutet der Abverkauf hat stark nachgelass­en,so das eine Wende rein techn. bevorsteht­.
Auch darf man nicht vergessen wo sie vor 6 Wochen stand: 9 US cent!  

übrigens,der Briefkurs in Frankfurt mit 0,016 unter dem Schlusskur­s in den USA-0,0215­ umgerechne­t knapp 0,017
Also: noch Schnäppche­npreis!  

jetzt bekommen die ersten Appetit ! wenn die in den usa nur twas höher heute nachmittag­ rein kommen gibt es hier keine mehr
unter 0,02!  

das wäre doch schön gibt es denn news oder irgendetwa­s neues?  

Umsatz in den ersten 15 min höher als die letzten Tage! Auch gutes Zeichen.Hi­er denken einige ebenso wie ich.  

ich hab mir auch gerade noch mal 60.000 gegönnt... ich will ja meinen teil zum volumen beitragen.­